|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FIRRE |
Gene summary for FIRRE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FIRRE | Gene ID | 286467 |
| Gene name | firre intergenic repeating RNA element | |
| Gene Alias | LINC01200 | |
| Cytomap | Xq26.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 286467 | FIRRE | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.76e-07 | 3.89e-01 | -0.059 |
| 286467 | FIRRE | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.65e-17 | 5.28e-01 | 0.0674 |
| 286467 | FIRRE | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.78e-13 | 5.99e-01 | 0.281 |
| 286467 | FIRRE | A002-C-203 | Human | Colorectum | FAP | 9.66e-04 | 3.26e-01 | 0.2786 |
| 286467 | FIRRE | A001-C-104 | Human | Colorectum | FAP | 1.33e-02 | 2.82e-01 | 0.0184 |
| 286467 | FIRRE | AEH-subject1 | Human | Endometrium | AEH | 1.44e-13 | 3.16e-01 | -0.3059 |
| 286467 | FIRRE | LZE7T | Human | Esophagus | ESCC | 4.33e-11 | 4.31e-01 | 0.0667 |
| 286467 | FIRRE | LZE22T | Human | Esophagus | ESCC | 1.57e-02 | 2.22e-01 | 0.068 |
| 286467 | FIRRE | LZE24T | Human | Esophagus | ESCC | 1.80e-03 | 1.28e-01 | 0.0596 |
| 286467 | FIRRE | P1T-E | Human | Esophagus | ESCC | 1.05e-09 | 3.99e-01 | 0.0875 |
| 286467 | FIRRE | P2T-E | Human | Esophagus | ESCC | 3.75e-03 | 9.70e-02 | 0.1177 |
| 286467 | FIRRE | P4T-E | Human | Esophagus | ESCC | 9.91e-08 | 1.96e-01 | 0.1323 |
| 286467 | FIRRE | P8T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.73e-01 | 0.0889 |
| 286467 | FIRRE | P10T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.28e-01 | 0.116 |
| 286467 | FIRRE | P20T-E | Human | Esophagus | ESCC | 3.34e-15 | 3.19e-01 | 0.1124 |
| 286467 | FIRRE | P22T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.31e-01 | 0.1236 |
| 286467 | FIRRE | P23T-E | Human | Esophagus | ESCC | 2.33e-11 | 2.97e-01 | 0.108 |
| 286467 | FIRRE | P26T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.23e-01 | 0.1276 |
| 286467 | FIRRE | P27T-E | Human | Esophagus | ESCC | 9.53e-09 | 2.21e-01 | 0.1055 |
| 286467 | FIRRE | P28T-E | Human | Esophagus | ESCC | 6.56e-15 | 2.78e-01 | 0.1149 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Thyroid | PTC |  |
| Thyroid | goiters |  |
| Thyroid | ATC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |